Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14736807 | 1.00 | CHRM2 (0.34) | CHRM2CHRM1CHRM3GBA1 | |
| SCHEMBL14736393 | 1.00 | CHRM2 (0.34) | CHRM2CHRM1CHRM3GBA1 | |
| Hydrochloric Acid SCHEMBL4179385 | 0.73 | GBA1 (0.36) | GBA1 | |
| SCHEMBL30601918 | 0.73 | MAPK1 (0.31) | — | |
| SCHEMBL7937595 | 0.73 | CHRM2 (0.36) | CHRM2CHRM1CHRM3 | |
| SCHEMBL7937593 | 0.73 | CHRM2 (0.36) | CHRM2CHRM1CHRM3 | |
| SCHEMBL20586469 | 0.71 | DDB1 (0.33) | CHRM2CHRM1CHRM3 | |
| SCHEMBL15240480 | 0.69 | CHRM2 (0.32) | CHRM2CHRM1CHRM3 | |
| SCHEMBL9852807 | 0.68 | BTK (0.34) | — | |
| SCHEMBL14964937 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742131-B2 | 7-azoniabicyclo [2.2.1] heptane derivatives, methods of production, and pharmaceutical uses thereof | THERON PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130059898-A1 | 7-AZONIABICYCLO [2.2.1] HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | THERON PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059898-A1 | 7-AZONIABICYCLO [2.2.1] HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | CHRM3, CHRM2, CHRM1 | CHRM2 2/4885CHRM1 3/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.